Explore a selection of our essential drug information below, or:
Identification
- Summary
Viper antivenom is an equine-derived antivenin used to manage North American Pit viper envenomation.
- Brand Names
- Anavip
- Generic Name
- Viper antivenom
- DrugBank Accession Number
- DB14114
- Background
Viper antivenom consists of antibodies derived from horses immunized and subsequently developed antibodies against snake venoms. ANAVIP, an equine-derived antivenom made with venom from Bothrops asper and Crotalus durissus, was first approved by the FDA on October 1, 2015, for the management of North American rattlesnake envenomation.1
- Type
- Biotech
- Groups
- Approved
- Synonyms
- Antivenin (bothrops atrox/crotalus adamanteus/crotalus atrox/crotalus durissus terrificus) (equine)
- Antivenin (crotalidae) polyvalent (equine origin)
- Antivenin (crotalidae) polyvalent (equine)
- Antivenin crotaline (pit-viper) equine immune F(ab)2)
- Antivenin, crotalidae polyvalent, equine
- Antivenin,crotalidae polyvalent
- Crotalid antivenin (equine)
- Crotalidae immune F(ab')2 (equine)
- Crotalidae polyvalent antivenin (equine)
- Crotaline antivenin
- Crotaline antivenin, polyvalent
- Pit viper (crotalid) antivenin (equine)
- Pit viper (crotalidae) antivenin (equine)
- Pit viper (crotalinae) antivenin (equine)
- Pit viper (crotalinae) immune antivenin (equine)
- Pit viper (crotalinae) immune globulin (equine)
- Pit viper (crotalinae) immune globulin antivenin (equine)
- Pit viper (crotalinae) immunoglobulin (equine)
- Polyvalent crotalidae antivenin
- Polyvalent crotalidae antivenin (equine)
Pharmacology
- Indication
Equine-derived viper antivenom is indicated for the management of adult and pediatric patients with North American Pit Viper envenomation.2
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Management of American rattlesnake envenomation •••••••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Viper antivenom works as an antidote to venom toxins of viper snakes.2
- Mechanism of action
Viper antivenom contains venom-specific F(ab’)2 fragments of immunoglobulin G (IgG) that bind and neutralize venom toxins, facilitating redistribution away from target tissues and elimination from the body.2
- Absorption
Following intravenous administration in healthy subjects, the mean (SD) area under plasma concentration versus time curve 4144 (670) µgxh/mL.2
- Volume of distribution
Following intravenous administration in healthy subjects, the mean (SD) steady-state volume of distribution was 3.3 (0.9) L.2
- Protein binding
There is no information available.
- Metabolism
There is no information available.
- Route of elimination
There is no information available.
- Half-life
Following intravenous administration in healthy subjects, the mean (SD) elimination half-life was 133 (53) L.2
- Clearance
Following intravenous administration in healthy subjects, the mean (SD) total clearance was 22 (7) mL/h.2
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
There is limited information available regarding the LD50 and overdose of viper antivenom.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Anavip Injection, powder, lyophilized, for solution 12 mg/1mL Intravenous Rare Disease Therapeutics, Inc. 2015-05-06 Not applicable US 
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image SUERO ANTIOFIDICO POLIVALENTE. Viper antivenom (70 mg) + Viper antivenom (10 mg) Solution Intravenous INSTITUTO NACIONAL DE SALUD 2012-03-26 Not applicable Colombia 
SUERO ANTIOFIDICO POLIVALENTE. Viper antivenom (70 mg) + Viper antivenom (10 mg) Solution Intravenous INSTITUTO NACIONAL DE SALUD 2012-03-26 Not applicable Colombia
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 92VV7G83ED
- CAS number
- Not Available
References
- General References
- Wilson BZ, Larsen J, Smelski G, Dudley S, Shirazi FM: Use of Crotalidae equine immune F(ab')2 antivenom for treatment of an Agkistrodon envenomation. Clin Toxicol (Phila). 2021 Nov;59(11):1023-1026. doi: 10.1080/15563650.2021.1892718. Epub 2021 Mar 11. [Article]
- FDA Approved Drug Products: ANAVIP [crotalidae immune F(ab’)2 (equine)] Lyophilized Powder for Solution for Injection For Intravenous Use Only [Link]
- External Links
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data3 Completed Treatment Snake Bite 1 somestatus stop reason just information to hide 2 Completed Treatment Coagulation Disorder / Snake Bite 1 somestatus stop reason just information to hide 2 Suspended Treatment Daboia Siamensis Envenoming 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, powder, lyophilized, for solution Intravenous 12 mg/1mL Solution Intravenous - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at June 22, 2018 20:20 / Updated at October 12, 2023 21:51